Checkpoint Responses in Cancer Therapy by Wei DaiCheckpoint Responses in Cancer Therapy by Wei Dai

Checkpoint Responses in Cancer Therapy

EditorWei Dai

Paperback | November 19, 2010

Pricing and Purchase Info


Earn 1,495 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


Extensive research has uncovered a set of molecular surveillance mechanisms - commonly called "checkpoints" - which tightly monitor cell-cycle processes. Today's anticancer drug development has identified many of these cell-cycle checkpoint molecules as effective targets. Research now promises to uncover a new generation of anticancer drugs with improved therapeutic indices based on their ability to target emerging checkpoint components. Checkpoint Responses in Cancer Therapy summarizes the advances made over the past 20 years, identifying components of cell-cycle checkpoints and their molecular regulation during checkpoint activation and validating the use of checkpoint proteins as targets for the development of anticancer drugs. This book's distinguished panel of authors takes a close look at topics ranging from the major molecular players affecting DNA synthesis and the response to DNA damage to advances made in the identification of chemical compounds capable of inhibiting individual mitotic kinases. Illuminating and authoritative, Checkpoint Responses in Cancer Therapy offers a critical summary of findings for researchers in the pharmaceutical and biotechnology industries and a valuable resource for academic scientists in cancer research and the study of cell-cycle regulation, signal transduction and apoptosis.
Title:Checkpoint Responses in Cancer TherapyFormat:PaperbackDimensions:328 pagesPublished:November 19, 2010Publisher:Humana PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:161737847X

ISBN - 13:9781617378478

Look for similar items by category:


Table of Contents

Preface  Action of the RB pathway in response to therapeutic agents Erik S. KnudsenTargeting the p53/MDM2 pathway for cancer therapy Lyubomir T. VassilevDNA topoisomerases as targets for the chemotherapeutic treatment of cancer Neil OsheroffTargeting the DNA damage checkpoint (ATM/ATR) Wafik S. El-Deiry (Not in yet)Compounds that abrogate the G2 checkpoint Takumi KawabeCDK inhibitors as anti-cancer agents J. de BonoCHFR as a potential anti-cancer target T. TokinoAntimicrotubule agents M. Villalona-CaleroKinesin motor inhibitors as effective anti-cancer drugs A. GiannisTargeting the spindle checkpoint in cancer chemotherapy Hongtao Yu Anti-proliferation inhibitors targeting aurora kinases Daruka MahadevanPlks as novel targets for cancer drug design Wei DaiDo histone deacetylase inhibitors target cell cycle checkpoints that monitor heterochromatin structure? Brian G. Gabrielli